ESPE Abstracts (2014) 82 P-D-2-1-536

Monitoring GnRH Analog Treatment in Girls with Central Precocious Puberty: a Comparison of Four Methods

Amnon Zunga, Ella Burundukova, Mira Ulmanb, Tamar Glasera, Malka Chenb & Zvi Zadika

aPediatric Endocrinology Unit, Kaplan Medical Center, Rehovot, Israel; bEndocrine Laboratory, Kaplan Medical Center, Rehovot, Israel

Background: The gold standard for adequate hormonal suppression during GnRHa treatment for precocious puberty (PP) is attenuated serum LH levels in response to LHRH stimulation.

Objective and hypotheses: We aimed to compare basal and post-GnRHa levels of LH to LHRH stimulation test, and to evaluate first-voided urinary LH (ULH) as a non-invasive alternative method for monitoring treatment.

Method: Seventeen girls with PP were followed over 12–36 months during GnRHa (Decapeptyl) treatment. ULH and serum LH levels were obtained every 4 months before and 24 h after GnRHa administration respectively, along with clinical evaluation of pubertal staging, growth velocity (GV) and bone age (BA) advancement. LHRH stimulation test was performed annually. ULH cutoff was 1.62 IU/l based on 2 S.D. above the mean in 29 pre-pubertal girls.

Results: A total of 36 LHRH stimulation tests demonstrated adequate suppression of gonadotropins with peak LH of 0.57±0.33 (0.1–1.4 IU/l). Corresponding mean post-GnRHa LH levels was 0.59±0.33 (0.1–1.6) and mean basal LH levels was 0.27±0.16 (0.1–0.7 IU/l). Both tests were correlated with LHRH-stimulated LH: R=0.807 and R=0.696 respectively (P<0.001). Corresponding mean ULH levels was 1.12±0.38 IU/l. Among 90 pair-tests of ULH and post-GnRHa LH measurements obtained over 380 patient-months, six ULH measurements levels were above the pre-pubertal cutoff (range 1.66–2.21) but none of post-GnRHa LH levels. In spite of adequate hormonal suppression, 21 episodes of clinical breakthrough were recorded: 13 episodes of GV-SDS >2 and 11 episodes of BA advancement. ULH and post GnRH LH levels measured during these episodes were similar to levels obtained during clinical suppression.

Conclusion: Decapeptyl Depot treatment provides adequate suppression of the hypothalamic – pituitary – gonadal axis during PP. When in doubt, both pre-GnRHa and post-GnRHa LH levels can provide reliable data on hormonal suppression. Clinical breakthroughs during treatment do not reflect unsuppressed gonadotropins and therefore therapy intensification is not necessarily indicated.

Article tools

My recent searches

No recent searches.